Related by context. All words. (Click for frequent words.) 73 receiving golimumab 69 achieved CCyR 67 achieved ACR# 66 relapsed MM 66 PLX STROKE targeting 66 receiving VELCADE 66 anaphylactic reactions bronchospasm 65 certolizumab 65 severe exacerbations 65 prednisone prednisolone plus 65 plus methotrexate 65 oral rivaroxaban 65 HBeAg negative patients 65 atazanavir ritonavir 65 ExTRACT TIMI 65 deep venous thromboses 65 8mg/kg 65 plus prednisone prednisolone 65 nondiabetic patients 65 ACTEMRA TM 65 EDARBI 64 Carotid Revascularization Endarterectomy vs. 64 galiximab 64 naïve HCV 64 fluvastatin 64 tolterodine ER 64 reduce serum phosphate 64 Mg Uk 64 NATRECOR ® 64 Infusion Reactions Severe 64 oxycodone CR 64 #mg dose [002] 64 elevated ALT 64 oral antidiabetic medication 64 Mg Usa 63 Hepatotoxicity 63 desvenlafaxine succinate 63 REYATAZ r arm 63 HBeAg positive patients 63 nonvertebral fractures 63 oxycodone IR 63 mitoxantrone plus 63 mg ustekinumab 63 ULORIC 63 infliximab monotherapy 63 venlafaxine XR 63 R# #mg BID 63 basal bolus regimen 63 perioperatively 63 anastrazole 63 Unstable Angina 63 recurrent glioblastoma multiforme 63 bortezomib refractory 63 receiving INTRON 63 tapentadol ER 63 Febrile neutropenia 62 severe hepatic dysfunction 62 lumbar spine BMD 62 titrated glipizide 62 mycophenolate mofetil 62 abacavir lamivudine 62 antiretroviral naïve 62 BARACLUDE ® 62 mcg BID 62 complete cytogenetic response 62 advanced adenomas 62 PREZISTA r arm 62 nicardipine 62 hsCRP levels 62 solifenacin 62 somatostatin analog 62 #.#/#.# mmHg [001] 62 Folfox 62 ZACTIMA 62 Navelbine R 62 TAXUS Liberte Long 62 Thrombotic events 62 adjunctive ABILIFY 62 #mg BID [001] 62 aldosterone antagonist 62 mg Pycnogenol 62 estramustine 62 Cariprazine 62 PASI scores 62 R adefovir dipivoxil 62 adjunctive placebo 62 morphometric vertebral fractures 62 MAGE A3 ASCI 61 receiving XGEVA 61 mg BID dose 61 bone marrow reticulin deposition 61 eritoran 61 Amgen Neulasta R 61 Arch Intern Med 61 receiving TNF blockers 61 tarenflurbil 61 myocardial infarction ventricular fibrillation 61 dalteparin 61 symptomatic intracranial 61 Ribavirin causes 61 serum phosphate 61 HCV RESPOND 2 61 cilostazol 61 undergone radical prostatectomy 61 mcg kg REBETOL 61 tipranavir ritonavir 61 stage IIIb IV 61 ritonavir boosted 61 develop HBV reactivation 61 AML MDS 61 Lipitor #mg 61 neutropenia dehydration dyspnea 61 antiretroviral naive 61 atorvastatin #mg 61 Erythropoietic therapies may 61 TEAEs 61 lymphocytosis 61 Hypotension 61 XIENCE V demonstrated 61 NATRECOR R 61 irbesartan 61 Paxil paroxetine 61 mcg QD 61 HBeAg seroconversion 61 Severe acneform rash 61 Val HeFT 61 PROCTOCORT ® Suppository Hydrocortisone 61 thrombocytopenic 61 Platinol ® cisplatin 61 FluCAM arm 61 invasive aspergillosis 61 intravenous bisphosphonates 61 Subgroup analysis 61 CLARITY TIMI 61 QTc prolongation 60 β blockers 60 ZOLINZA 60 achieved sustained virologic 60 beta carotene supplementation 60 underwent surgical resection 60 refractory NSCLC 60 Pemetrexed 60 amalgam fillings mercury vapor 60 mg QD 60 riociguat 60 papillary renal cell carcinoma 60 antiplatelet medications 60 invasive lobular 60 FUSILEV enhances 60 Xelox 60 Flu Cy 60 Elotuzumab 60 LymphoStat B belimumab 60 treatment naive genotype 60 Avandia Actos 60 PRADAXA #mg 60 angiographic outcomes 60 mL/min/#.# m 2 60 hyperphenylalaninemia HPA due 60 Valcyte tablets 60 azilsartan medoxomil 60 recurrent venous thromboembolism 60 plus COPEGUS 60 tolvaptan 60 discontinuations due 60 KRAS mutant tumors 60 virologically suppressed 60 plus dexamethasone 60 arterial thromboembolic events 60 receiving prophylactic anticoagulation 60 5mg dose 60 FOLFOX4 60 zoledronic acid Reclast 60 hepatorenal syndrome 60 ximelagatran 60 achieved PASI 60 follicular lymphomas 60 underwent CABG 60 landmark ATHENA 60 Renal impairment 60 CYP#A# substrate 60 receiving immunosuppressive therapy 60 events TEAEs 60 RoACTEMRA 60 methotrexate monotherapy 60 ertapenem 60 ATACAND 60 underwent resection 60 LEXIVA r 60 DLTs 60 CIMZIA TM certolizumab pegol 60 recurrent VTE 60 EXJADE 60 ribavirin therapy 60 Cholesterol Levels SPARCL 60 tamoxifen Nolvadex ® 59 HCV SPRINT 59 r hGH 59 REMICADE ® 59 intravascular hemolysis 59 pretreatment serum 59 dexamethasone intravitreal implant 59 EGRIFTA ™ tesamorelin 59 multicenter placebo controlled 59 BEXXAR Therapeutic Regimen 59 SSRI SNRI 59 HBeAg negative 59 ovarian endometrial 59 HBV infections 59 oral antidiabetes 59 nadroparin 59 placebo dexamethasone 59 resected pancreatic cancer 59 interferon ribavirin 59 XIENCE V PROMUS Stent 59 Dementia Related Psychosis 59 brand ciclesonide HFA 59 BoNTA 59 glycated hemoglobin levels 59 metastatic GIST 59 biliary tract cancer 59 CYT# potent vascular disrupting 59 finasteride Proscar 59 reinfarction 59 chronic HBV 59 BARACLUDE R 59 accompanying electrolyte abnormalities 59 ® atorvastatin calcium 59 PREZISTA r 59 antiangiogenic therapy 59 INTEGRILIN R 59 alanine aminotransferase 59 entecavir 59 BENICAR HCT 59 demonstrated antitumor activity 59 mg TID 59 amoxicillin clavulanate 59 advanced adenoma 59 mcg albinterferon alfa 2b 59 alicaforsen enema 59 CIMZIA ™ 59 Dabigatran etexilate 59 undetectable HBV DNA 59 DAS# remission 59 lipid lowering drugs 59 reactogenicity 59 KRAS mutations occur 59 -#.# mg dL [002] 59 sirolimus stent 59 rosuvastatin #mg 59 included exfoliative dermatitis 59 STRIDE PD 59 benazepril 59 hormone receptor negative 59 null responder HCV 59 liver histology 59 nucleoside naive 59 gemcitabine carboplatin 59 biologic DMARD 59 ARCOXIA 59 oral diclofenac 59 anthracycline taxane 59 locoregional recurrence 59 biochemical relapse 59 serum phosphorous 59 severe renal impairment 59 PROSTVAC VF 59 definite stent thrombosis 59 TAXUS Express Stent 59 #mg QD [002] 59 Pharmacokinetic parameters 59 Hypertensive adverse reactions 59 INVEGA ® SUSTENNA ® 59 headache abdominal pain 59 TMC# r 59 NMIBC 59 squamous histology 59 corticosteroid dose 59 resectable pancreatic cancer 59 generalized edema 59 ORAL Solo 59 EURIDIS 59 CYPHER Stent 59 ACR# response 59 achieved statistical significance 59 BRIM2 59 rFVIIa 59 MCyR 58 venous thromboembolisms 58 AVERROES 58 chlorambucil 58 pyrexia mucositis sepsis febrile 58 TNF antagonist 58 de novo AML 58 REMINYL ® 58 progressive PsA 58 Doxil ® 58 FDA Approves Novel 58 relapsed myeloma 58 VADT 58 kidney urologic 58 Raptiva r 58 recurrent genital herpes 58 symptomatic VTE 58 binary restenosis 58 non valvular atrial 58 anagrelide 58 haematologic 58 unstable angina UA 58 prospectively stratified 58 aplastic anemia AA 58 recurrent atrial fibrillation 58 ST Elevation Myocardial 58 NSAID associated 58 RRMS patients 58 serum urate levels 58 CCyR 58 nadolol 58 heFH 58 NSABP B 58 blinded randomized placebo controlled 58 variant angina 58 HIV HCV coinfected 58 poor metabolizers 58 intravenous bolus 58 Tasigna prolongs 58 Kaplan Meier analysis 58 Postoperative complications 58 adalimumab 58 neutrophil counts 58 β blocker 58 ToGA 58 dyslipidemia hypertension diabetes 58 alfa 2a 58 endometrial hyperplasia 58 ALT flares 58 ischemia driven 58 ELOXATIN 58 neurologic progression 58 systemic corticosteroid 58 simvastatin ezetimibe 58 chronic lyme 58 taxane resistant 58 INVEGA ® 58 CTAP# Capsules 58 rimonabant #mg 58 ACR# responses 58 sunitinib Sutent 58 steroid dexamethasone 58 Triapine R 58 Warach 58 prednisone prednisolone 58 lipid lowering agents 58 postoperative chemotherapy 58 serum creatinine levels 58 CR nPR 58 thyrotropin levels 58 lenalidomide Revlimid R 58 rt PA 58 targeting miR 58 venous thromboembolic disease 58 TAXUS VI 58 pCR 58 TRITON TIMI 58 ruboxistaurin 58 beta blockers ACE inhibitors 58 gemfibrozil 58 undergoing peritoneal dialysis 58 CK # plasma concentrations 58 3mg/kg 58 undergone splenectomy 58 recurrent DVT 58 moderate renal impairment 58 lopinavir r arm 58 AVOREN 58 APTIVUS r 58 pravastatin Pravachol 58 splenectomized patients 58 colorectal adenoma 58 3TC lamivudine Epivir 58 mycophenolate mofetil MMF 58 microbiologically evaluable 58 % CI #.#-#.# [007] 58 number NCT# ClinicalTrials.gov 58 salmeterol fluticasone 58 Naive Patients 58 BCG refractory carcinoma 58 BARI 2D 58 aspirin clopidogrel 58 TDF FTC 58 liver transplant recipients 58 Stenting Trial CREST 58 ECASS 58 teriflunomide 58 4mg/kg 58 decompensated liver disease 57 Response Evaluation Criteria 57 Non inferiority 57 Median PFS 57 rebleeding 57 RE LY 57 unfractionated heparin UFH 57 diarrhea flatulence 57 Plaque Psoriasis 57 vitamin B# folic acid 57 GnRH agonists 57 Serious Adverse Events 57 Arixtra ® 57 evaluating mipomersen 57 Crohn Disease Activity 57 AVANDIA 57 dose escalation phase 57 boosted protease inhibitor 57 paliperidone ER 57 pegylated alpha interferon 57 serum phosphate levels 57 SIMCOR 57 fluvastatin Lescol 57 coinfected patients 57 dose Iluvien 57 differentiated thyroid 57 warfarin sodium 57 EDSS scores 57 indinavir 57 myopathy rhabdomyolysis 57 HAM D# scores 57 sorafenib Nexavar 57 iniparib BSI 57 low dose dexamethasone 57 annualized relapse 57 mg kg dose 57 eplerenone 57 remission CR 57 Ceplene/IL-2 57 COPAXONE R 57 TAXUS p value 57 Viread tenofovir disoproxil fumarate 57 novel VDA molecule 57 standard chemotherapy regimen 57 statin cholesterol lowering 57 CALGB # [002] 57 bepotastine besilate nasal spray 57 transaminase elevations 57 RECORD1 57 Serevent salmeterol 57 previously untreated follicular 57 serum leptin 57 ARIXTRA R 57 Recurrent Glioblastoma 57 weekly CSBMs 57 mCRPC 57 fewer uterine cancers 57 HER2 expression 57 monoinfected patients 57 Thrombolysis 57 MGd 57 mg administered orally 57 Randomized Phase II 57 sustained virologic response 57 cyclophosphamide methotrexate 57 q8h 57 TMP SMX 57 preoperative chemotherapy 57 cobiprostone 57 Warfarin Coumadin 57 piperacillin tazobactam 57 recurrent malignant glioma 57 strontium ranelate 57 brivanib 57 -#.# log# 57 ginkgo biloba extract 57 workhorse lesions 57 NS5B polymerase 57 suboptimal adherence 57 thrombotic events 57 plus MTX 57 glycoprotein IIb IIIa inhibitor 57 Naproxen sodium 57 circulating EPCs 57 dopamine partial agonist 57 HGS ETR1 mapatumumab 57 Seroquel quetiapine fumarate 57 MADRS score 57 nilotinib 57 pyridostigmine 57 NPH insulin 57 serum phosphorus 57 RE LY ® 57 CrCl 57 dosed orally 57 recurrent myocardial infarction 57 SORT OUT III 57 de novo kidney transplant 57 levetiracetam 57 nondiabetics 57 Commonly prescribed 57 mg hydrochlorothiazide 57 baseline serum creatinine 57 High Dose quadruples 57 symptomatic pulmonary embolism 57 colesevelam HCl 57 darunavir ritonavir 57 achieved sustained virological 57 low dose Iluvien 57 retrospective cohort 57 ONTARGET 57 Free Survival PFS 57 Zemplar Capsules 57 Tumor shrinkage 57 achieve sustained virologic 57 daily subcutaneous injections 57 LEXIVA 57 Neoadjuvant 57 CAMMS# 57 #mg BID [003] 57 Renal Cell Carcinoma RCC 57 subcutaneous PRO 57 aldosterone antagonists 56 unstable angina pectoris 56 smoldering multiple myeloma 56 ENDEAVOR III 56 transrectal ultrasound guided 56 undergoing elective percutaneous 56 #.#mg/dL 56 undergoing coronary artery 56 fibrate drugs 56 Screening Trial DMIST 56 endometriosis ovarian cysts 56 saline placebo 56 Study ARIC 56 cisplatin chemotherapy 56 lopinavir ritonavir Kaletra 56 ACCOMPLISH 56 Rosuvastatin JUPITER 56 multicenter randomized placebo controlled 56 QT interval prolongation 56 vaccinees 56 ispinesib administered 56 Percutaneous Coronary Intervention 56 underwent coronary angiography 56 oral FTY# 56 A1c levels 56 myocardial infarctions 56 HIV coinfected 56 Thal Dex 56 antidepressants fluoxetine 56 Bayer HealthCare Onyx Pharmaceuticals 56 perioperative complications 56 peginterferon alfa 2a 56 DES implantation 56 INFERGEN 56 antiarrhythmic drug 56 CRESTOR #mg 56 hematologic toxicity 56 maximal doses 56 bazedoxifene conjugated estrogens 56 Stent thrombosis 56 #mg/m# [002] 56 multicenter randomized controlled 56 symptomatic carotid stenosis 56 #mg ATC 56 Lupuzor ™ 56 aminotransferase elevations greater 56 carotid endarterectomy CEA 56 Celebrex celecoxib 56 ENGAGE AF TIMI 56 nucleotide analogue 56 cerebrovascular events 56 IFN alfa 56 tenecteplase 56 cytogenetic response 56 Capsules CII 56 ARIXTRA 56 angiotensin converting enzyme inhibitor 56 active comparator 56 stroke hypertension palpitations 56 sUA 56 Provent Therapy 56 CR CRu 56 ARB telmisartan 56 BRIM3 56 Bacillus Calmette Guerin BCG 56 CVD mortality 56 hepatotoxicity 56 detectable HCV RNA 56 PREVENT IV 56 recurrent ischemia 56 patients undergoing CABG 56 Welchol 56 tirofiban 56 H2 blocker 56 variceal bleeding 56 mm Stent 56 NUCYNTA ™ 56 silent ischemia 56 Clostridium Difficile Associated 56 Torsades de Pointes 56 transfusion syndrome 56 sulfonylurea metformin 56 maximally tolerated dose 56 Related Anemia 56 coronary insufficiency 56 atypical ductal hyperplasia 56 containing abacavir 56 KRAS status 56 nonfatal MI 56 chronically immunosuppressed solid 56 pegnivacogin 56 CINQUIL 56 isoproterenol 56 MACCE 56 Randomized Controlled 56 atypical femur fractures 56 postoperative pathology 56 Peptide YY 56 q#h 56 drug eluting stent implantation 56 DAPT 56 nonnucleoside reverse transcriptase inhibitors 56 thromboembolic complications 56 carotid artery blockage 56 CHAMPION PCI 56 atherothrombotic events 56 APTIVUS 56 mg/m2 dose 56 hepatic metastases 56 myocardial infarctions MIs 56 Castration Resistant Prostate Cancer 56 PRIMO CABG 56 avosentan 56 LEVAQUIN ® 56 beta blocker therapy 56 HER2 positive cancers 56 potassium sparing 56 dutasteride 56 GERD symptom 56 Paliperidone ER 56 CsA 56 anthracyclines taxanes 56 Tumor Response 56 prospectively enrolled 56 stable angina 56 ENESTnd 56 cyclophosphamide Cytoxan 56 glomerular filtration 56 Arch Surg 56 periprocedural 56 Elitek 56 C1 INH deficiency 56 HbA1C levels 56 Subgroup analyzes 55 postintervention 55 HYVET 55 CHARM Added 55 hemostatic efficacy 55 elevated LDL cholesterol 55 Adjuvant chemotherapy 55 idraparinux 55 DOI #.#/art.# 55 oral prednisolone 55 % CI #.#-#.# [003] 55 sevelamer 55 plasma uric acid 55 via intradermal injections 55 tumor progression TTP 55 Digital Mammographic Imaging 55 PKC# 55 anticlotting drugs 55 SUSTENNA TM 55 glycated hemoglobin HbA1c 55 paclitaxel eluting stents 55 hypercalcemia 55 mg BID 55 TAXUS Stent 55 candesartan 55 rtPA 55 acute STEMI 55 Index CDAI 55 mRCC 55 events MACE 55 heparin induced thrombocytopenia 55 MEND CABG 55 hypersensitivity allergic reactions 55 revascularizations 55 XELOX 55 prospective multicentre 55 imatinib therapy 55 cerebral microbleeds 55 pegylated interferon alpha 55 Gemzar ® 55 stent thromboses 55 pegylated interferon alfa 55 serum potassium 55 refractory ischemia 55 receiving Vectibix monotherapy 55 visceral metastases 55 adverse cytogenetics 55 FOLPI 55 Lamictal XR 55 prostate TURP 55 placebo PBO 55 serum lipid levels 55 CALERIE 55 Diamyd r 55 mg subcutaneous 55 thrombotic complications 55 Antibiotic resistant infections 55 newer antipsychotics 55 FOLFIRI 55 GP IIb IIIa inhibitors 55 underwent percutaneous coronary 55 asymptomatic carotid stenosis 55 ID TLR 55 CONCERTA 55 OPT CHF 55 evaluable subjects 55 rheumatoid arthritis osteoarthritis ankylosing 55 diuretics beta blockers 55 Selzentry Celsentri 55 statins cholesterol lowering 55 HER2 overexpression 55 IOP lowering 55 HGPIN 55 extracolonic findings 55 Wisconsin Sleep Cohort 55 Prostate Cancer Prevention 55 Patient Outcomes 55 Tesmilifene 55 Viral load 55 Inegy 55 adjuvant radiotherapy 55 Gilead Viread 55 cerebrovascular accidents 55 Dr. Kandzari 55 antidiabetic medication 55 noninferior 55 olaparib 55 R rilonacept Injection 55 rolofylline 55 rosuvastatin 55 MERLIN TIMI 55 SPARCL 55 antibody titer 55 Index CDAI score 55 postoperative mortality 55 inflammatory lesions 55 plus gemcitabine 55 relapsed refractory multiple myeloma 55 severe neutropenia 55 infarction NSTEMI 55 Pegylated Liposomal Doxorubicin 55 LHRH analogues 55 histologically confirmed 55 erlotinib Tarceva ® 55 infective endocarditis 55 lowering homocysteine levels 55 chronic thromboembolic pulmonary 55 receiving VICTRELIS 55 FRAGMIN 55 prostate cancer CaP 55 ticlopidine 55 Primary endpoints 55 hypomagnesemia 55 placebo fluoxetine 55 Corona crewmembers 55 Prostate AdenoCarcinoma Treatment 55 inhospital 55 SIMPADICO 55 gout flares 55 MERIT ES 55 Serious anaphylactoid reactions 55 conducted retrospective cohort 55 ® pioglitazone HCl 55 EBMT criteria 55 nevirapine Viramune 55 trivalent inactivated influenza 55 plus aztreonam 55 timepoints 55 platelet dysfunction 55 vaginal candidiasis 55 thromboembolic events 55 Hb A1C 55 conjugated equine estrogen 55 accusers extorted money 55 concomitant antibiotics 55 serum clusterin levels 55 PSADT 55 plus GP IIb 55 oral rehydration IV 55 venous thromboembolic events 55 protein excretion 55 prospective nonrandomized 55 CIN3 55 ISTA Pharmaceuticals Announces 55 progesterone receptor negative 55 calculated creatinine clearance 55 NSTE ACS 55 HORIZONS AMI 55 peginterferon 55 mg qd 55 bronchodilatory 55 thromboses 55 everolimus eluting stents 55 deferoxamine 55 lipohypertrophy 55 eculizumab therapy 55 recurrent GBM 55 underwent angiography 55 metastatic malignant melanoma 55 metformin monotherapy 55 either acutely decompensated 55 antiplatelet drugs 55 ketorolac 55 metastatic CRC 54 undergoing coronary angiography 54 ribavirin RBV 54 Stage IIB 54 placebo dummy pill 54 HPV-#/# 54 postoperative inflammation 54 Phase III AFFIRM 54 protease inhibitor PI 54 J Clin Oncol 54 dosing frequency 54 androgen suppression 54 hip BMD 54 Platelet counts 54 alteplase 54 HER2 amplified 54 noncardiovascular 54 estimated glomerular filtration 54 median PFS 54 androgen depletion therapy 54 renal cell carcinomas 54 corticosteroid therapy 54 CRp 54 pulmonary exacerbations 54 chorioamnionitis 54 infusional 54 COREG 54 prescribed statins 54 recurrent metastatic 54 sirolimus eluting stents 54 vertebral fracture 54 asymptomatic PAD 54 perioperative mortality 54 invasive fungal infection 54 metastatic lung cancer 54 dose dexamethasone 54 prospectively defined 54 ONGLYZA 54 Bextra valdecoxib 54 ipsilateral stroke 54 Randomized Evaluation 54 placebo controlled clinical 54 TAXUS IV 54 conjugated estrogen 54 Myocardial Infarction Study 54 cardiovascular calcification 54 dose atorvastatin 54 Multaq tablets 54 febrile neutropenia 54 stented artery 54 Lofexidine 54 macrovascular events 54 maximal tolerated 54 sustained virological response 54 renal flares 54 tumor histology 54 ACUITY trial 54 antiandrogens 54 external genital lesions 54 IIIa inhibitors 54 postoperative complication 54 esthesioneuroblastoma rare form 54 HAV infection 54 Adenomas 54 SEROQUEL XR 54 ALLHAT 54 posttreatment 54 atherogenic dyslipidemia 54 neoadjuvant 54 nonfatal myocardial infarction MI 54 nonmetastatic 54 serum GGT 54 Multicenter Automatic Defibrillator Implantation 54 patients coinfected 54 trastuzumab Herceptin ® 54 Zoraxel 54 pyrimidine nucleoside analog 54 PSA nadir 54 IIIa inhibitor 54 adrenal suppression 54 clinically meaningful reductions 54 R brand eszopiclone 54 pT3 54 diagnostic angiography 54 underwent balloon angioplasty 54 draining enterocutaneous 54 esomeprazole 54 Victoza R 54 Zemiva imaging 54 NHANES III 54 ENDEAVOR II 54 EMPHASIS HF trial 54 plasma HCV RNA 54 elevated bilirubin 54 severe mitral regurgitation 54 infections gastrointestinal perforations 54 baseline HbA1c 54 pertuzumab 54 painkillers methadone Oxycontin 54 Hemorrhagic stroke 54 oral prodrug 54 cystoid macular edema 54 #mg QD [001] 54 peripheral arterial occlusive disease 54 By EURSOC Two 54 BCIRG 54 elevated LDH 54 NSABP C 54 ALIMTA cisplatin 54 abiraterone acetate 54 Long Term Efficacy 54 subtrochanteric 54 preintervention 54 Randomized controlled 54 Univariate analysis 54 ADHF 54 invasive lobular carcinoma 54 ACCORD Lipid 54 pulls Darvon painkiller 54 LATUDA 54 Stage IIIb 54 tipranavir 54 graft occlusion 54 coronary revascularization procedures 54 serum urate 54 ELACYT 54 SVR# 54 stable angina pectoris 54 onset atrial fibrillation 54 SPIRIT FIRST 54 histologically proven 54 MADIT II 54 bone marrow reticulin 54 dosing cohort 54 PRIMO CABG2 54 repeat paracentesis 54 nonvertebral fracture 54 serum estradiol 54 CTEPH 54 histological subtype 54 Colon polyps 54 VIRAMUNE R 54 DBMD 54 Oropharyngeal Candidiasis 54 neurologic complications 54 JANUVIA 54 overt nephropathy 54 partial remissions 54 serum IGF 54 Hazard Ratio 54 assessing T DM1 54 BOLDER II 54 Operative mortality 54 Globicus coincident index 54 Abciximab 54 Intervention Effectiveness 54 cholinesterase inhibitor 54 genotypic resistance 54 Aeolus Pharmaceuticals Announces 54 PPSV# 54 pT2 54 demonstrated clinically meaningful 54 Antihypertensive 54 banned Darvon Darvocet 54 #rd Annual CTRC 54 MTP inhibitor 54 intracranial hemorrhage ICH 54 pancreatic resection 54 Albuferon albinterferon alfa 2b 54 hemoglobin A1c levels 54 popular antidepressant Paxil 54 Rimantadine 54 aminotransferase levels 54 ABCSG 54 intrahepatic bile duct 54 segment binary restenosis 54 pimecrolimus 54 lispro 54 LHRH agonists 54 Coronary Artery Bypass Graft 54 nonfasting triglycerides 54 Listeria infections 54 contradicted Metrolink 54 EXPLORE Xa 54 intima media thickness 54 budesonide inhalation suspension